Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 110.03 0.29 (0.26%) Market Cap: 6.94 Bil Enterprise Value: 10.90 Bil PE Ratio: 22.69 PB Ratio: 1.88 GF Score: 78/100

Q4 2019 Jazz Pharmaceuticals PLC Earnings Call Transcript

Feb 25, 2020 / 09:30PM GMT
Release Date Price: $127.25 (-2.76%)
Operator

Welcome to the Jazz Pharmaceuticals plc Full Year Fourth Quarter 2019 Financial Results Conference Call. Following an introduction from the company, we will open the call to questions. I will now turn the call over to Katherine Littrell, Head of Investor Relations at Jazz Pharmaceuticals.

Katherine A. Littrell
Jazz Pharmaceuticals plc - VP of IR

Thank you, Kevin, and thanks to those of you joining our investor call. Today, we reported our fourth quarter and full year 2019 financial results and provided financial guidance for 2020. The press release and the slide presentation accompanying this call are available in the Investors section of our website.

On the call today are Bruce Cozadd, CEO; Dan Swisher, President; and Rob Iannone, Executive Vice President, R&D. Joining for the Q&A session are Mike Miller, Executive Vice President, U.S. Commercial; Jed Black, Senior Vice President, Sleep and Neuroscience; Phil Jochelson, our Sleep and Neuroscience Therapeutic Head; Anne Borgman, our Hematology and Oncology Therapeutic Head; and Shawn Mindus,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot